Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Amit Agarwal is active.

Publication


Featured researches published by Amit Agarwal.


Clinical Lymphoma, Myeloma & Leukemia | 2018

Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)

Sundar Jagannath; Rafat Abonour; Brian G. M. Durie; Cristina Gasparetto; James W. Hardin; Mohit Narang; Howard R. Terebelo; Kathleen Toomey; Lynne I. Wagner; Shankar Srinivasan; Amani Kitali; Lihua Yue; E. Dawn Flick; Amit Agarwal; Robert M. Rifkin

Background: The treatment landscape for multiple myeloma (MM) has undergone recent changes with the regulatory approval of several new therapies indicated for second‐ and later‐line disease. Using data from Connect MM, the largest multisite, primarily community‐based, prospective, observational registry of MM patients in the United States, selection of second‐line treatments was evaluated during a 5‐year period from 2010 to 2016. Patients and Methods: Eligible patients were aged ≥ 18 years, had newly diagnosed MM ≤ 2 months before study entry, and were followed for up to 8 years. Patients who received ≥ 2 lines of therapy were analyzed. “Tepee” plots of stacked area graphs differentiated treatments by color to allow visualization of second‐line treatment trends in MM patients. Results: As of February 2017, 855 of 2897 treated patients had progressed to second‐line treatment. Treatment selection was heterogeneous; shifting patterns of treatment choices coincided with the approval status of newer agents. The most common treatment regimens in the early part of the decade were lenalidomide and/or bortezomib, with or without dexamethasone, with increasing use of newer agents (carfilzomib, pomalidomide, daratumumab, and elotuzumab) and triplet combinations over time. The influence of the baseline patient characteristics of age, history of diabetes, peripheral neuropathy, and renal function on treatment choice was also examined. Conclusion: These findings indicate that community physicians are current in their MM management practices, with uptake of new drugs and acquaintance with results of randomized clinical trials using combinations almost concurrent with their regulatory approval and publication. Micro‐Abstract Connect MM is a large prospective observational US‐based disease registry that was used to evaluate second‐line treatment patterns in patients with relapsed or refractory multiple myeloma during a 5‐year period, from 2010 to 2016. Treatment uptake was found to coincide with clinical milestones (ie, regulatory approvals, clinical study results), with growing preference for newer agents and triplet combinations over time.


Blood Advances | 2018

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM

Sundar Jagannath; Rafat Abonour; Brian G. M. Durie; Mohit Narang; Howard R. Terebelo; Cristina Gasparetto; Kathleen Toomey; James W. Hardin; Lynne I. Wagner; Amit Agarwal; Shankar Srinivasan; Amani Kitali; E. Dawn Flick; Michael Sturniolo; Robert M. Rifkin

Autologous stem cell transplantation (ASCT) followed by lenalidomide maintenance therapy is the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). Clinical trials show progression-free survival (PFS) benefits, with some studies (Cancer and Leukemia Group [CALGB] trial and meta-analysis) also showing overall survival (OS) benefits, but applicability to real-world clinical settings is unclear. Using data from Connect MM, the largest US-based observational registry of NDMM patients, we analyzed effects of maintenance therapy on long-term outcomes in 1450 treated patients enrolled from 2009 to 2011. Patients who received induction therapy and ASCT (n = 432) were analyzed from 100 days post-ASCT (data cut 7 January 2016): 267 received maintenance (80% lenalidomide-based [of whom 88% received lenalidomide monotherapy]); 165 did not. Lenalidomide maintenance improved median PFS and 3-year PFS rate vs no maintenance (50.3 vs 30.8 months [hazard ratio (HR), 0.62; 95% confidence interval (CI), 0.46-0.82; P < .001] and 56% vs 42%, respectively). Improvements in median OS and 3-year OS rate were associated with lenalidomide maintenance vs no maintenance (not reached in either group [HR, 0.54; 95% CI, 0.36-0.83; P = .005] and 85% vs 70%, respectively). Five hematologic serious adverse events were reported with lenalidomide maintenance (pancytopenia [n = 2], febrile neutropenia, anemia, and thrombocytopenia [n = 1 each]) and 1 with no maintenance (thrombocytopenia). Second primary malignancies occurred at rates of 1.38 and 2.19 events per patient-year in lenalidomide maintenance and no maintenance groups, respectively. Survival benefits associated with lenalidomide maintenance previously demonstrated in clinical trials were observed in this community-based Connect MM Registry.


Journal of Clinical Oncology | 2018

Treatment (tx) journeys in newly diagnosed multiple myeloma (NDMM) patients (pts): Results from the Connect MM Registry.

Sundar Jagannath; Robert M. Rifkin; Cristina Gasparetto; Kathleen Toomey; Brian G. M. Durie; James W. Hardin; Howard R. Terebelo; Lynne I. Wagner; Mohit Narang; Sikander Ailawadhi; Shankar Srinivasan; Ahmed YoussefAgha; Brian Ung; Amani Kitali; E. Dawn Flick; Amit Agarwal; Rafat Abonour


Journal of Clinical Oncology | 2018

Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM).

Sikander Ailawadhi; Philip L. McCarthy; Sarah A. Holstein; Gail Larkins; Weiyuan Chung; Shankar Srinivasan; Amit Agarwal; Sagar Lonial


Journal of Clinical Oncology | 2018

Drivers of phase-based costs in patients with multiple myeloma.

Abdalla Aly; Zoe Clancy; Brian Ung; Amit Agarwal; Ruchit Shah


Journal of Clinical Oncology | 2018

Maintenance (MT) treatment (Tx) after lenalidomide, bortezomib, and dexamethasone (RVD) induction and stem cell transplant (SCT) in high-risk (HR) patients (pts) with newly diagnosed multiple myeloma (NDMM): A real-world analysis.

Rafael Fonseca; Kejal Parikh; Brian Ung; Quanhong Ni; Amit Agarwal


Journal of Clinical Oncology | 2018

Predictors of long-term survival in newly diagnosed multiple myeloma (NDMM) patients (pts) enrolled in the Connect MM registry.

Cristina Gasparetto; Robert M. Rifkin; Howard R. Terebelo; Kathleen Toomey; Brian G. M. Durie; James W. Hardin; Sundar Jagannath; Lynne I. Wagner; Mohit Narang; Sikander Ailawadhi; E. Dawn Flick; Stanley Kotey; Shankar Srinivasan; Amani Kitali; Amit Agarwal; Rafat Abonour


Annals of Oncology | 2018

1007OImpact of initial treatment (tx) on HRQoL and outcomes in patients (pts) with newly diagnosed multiple myeloma (NDMM) without intent for immediate transplant (SCT): Results from the Connect® MM registry

Rafat Abonour; R M Rifkin; C. Gasparetto; K Toomey; Brian G. M. Durie; James W. Hardin; H R Terebelo; Sundar Jagannath; M Narang; Sikander Ailawadhi; Shankar Srinivasan; Amani Kitali; Amit Agarwal; Lynne I. Wagner


Journal of Clinical Oncology | 2017

Impact of post-autologous stem cell transplant (ASCT) maintenance therapy on outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) using the large prospective community-based Connect MM registry.

Sundar Jagannath; Rafat Abonour; Brian G. M. Durie; Jatin J. Shah; Mohit Narang; Howard R. Terebelo; Cristina Gasparetto; Kathleen Toomey; James W. Hardin; Lynne I. Wagner; Amit Agarwal; Shankar Srinivasan; Amani Kitali; Faiza Zafar; Michael Sturniolo; Robert M. Rifkin


Journal of Clinical Oncology | 2017

Impact of t(11;14) on outcomes in African American (AA) and non-AA (NAA) patients (Pts) with newly diagnosed multiple myeloma (NDMM): Connect MM registry.

Cristina Gasparetto; Rafat Abonour; Sundar Jagannath; Brian G. M. Durie; Jatin J. Shah; Mohit Narang; Howard R. Terebelo; Kathleen Toomey; James W. Hardin; Lynne I. Wagner; Shankar Srinivasan; Amani Kitali; E. Dawn Flick; Faiza Zafar; Amit Agarwal; Robert M. Rifkin

Collaboration


Dive into the Amit Agarwal's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Brian G. M. Durie

Cedars-Sinai Medical Center

View shared research outputs
Top Co-Authors

Avatar

James W. Hardin

University of South Carolina

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge